/PRNewswire/ The global dyslipidemia drugs market was valued at US$ 11.8 Bn in 2018 and is anticipated to rise at a CAGR of 3.5% during the forecast period,.
- As per many government and corporate organizations involved in the cholesterol medicine business, dyslipidemia is on the rise globally and is one of the most dangerous cardiovascular diseases -